Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2013 | 01:35pm CEST

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMPAX LABORATORIES INC
07/20 IMPAX LABORATORIES : Technical Reports on Drug Makers Equities -- TherapeuticsMD..
07/17 Dominion Diamond and Impax rise; FedEx and BlackRock fall
07/17 IMPAX LABORATORIES : Announces FDA Approval of its AB Rated Generic Concerta® (M..
07/14 IMPAX LABORATORIES : SS NOI BCCSS 00145 AGFA IMPAX The IMPAX system and services
07/06 IMPAX LABORATORIES : to Report Second Quarter 2017 Results on August 9, 2017
07/05 IMPAX LABORATORIES : Announces FDA Approval and Launch of Additional Strengths o..
06/29 IMPAX LABORATORIES : to Report Second Quarter 2017 Results on August 9, 2017
06/26 Purcell Julie & Lefkowitz LLP Is Investigating Impax Laboratories, Inc. for P..
06/08 IMPAX LABORATORIES : to Present at the Goldman Sachs 38th Annual Global Healthca..
06/07 ASTRAZENECA : enters agreement with Grunenthal to divest rights to migraine trea..
More news
News from SeekingAlpha
07/18 Premarket analyst action - healthcare
07/17 FDA OKs Impax Labs' generic Concerta; shares ahead 6% premarket
07/06 Impax Labs gets final FDA approval for generic of Novartis' Focalin XR
06/16 Valeant viewed brightly by Cantor, as specialty pharmas move past old model
06/16 Premarket analyst action - healthcare
Financials ($)
Sales 2017 792 M
EBIT 2017 99,4 M
Net income 2017 -76,0 M
Debt 2017 443 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 29,67
EV / Sales 2017 2,25x
EV / Sales 2018 2,18x
Capitalization 1 338 M
Chart IMPAX LABORATORIES INC
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Technical analysis trends IMPAX LABORATORIES INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 16,8 $
Spread / Average Target -7,3%
EPS Revisions
Managers
NameTitle
Paul M. Bisaro President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Jeffrey D. Nornhold Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
IMPAX LABORATORIES INC36.98%1 338
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378
MERCK AND COMPANY6.39%171 303